Total Payments
$24,246
2024 Payments
$2,760
Companies
10
Transactions
43
Medicare Patients
579
Medicare Billing
$65,287
Payment Breakdown by Category
Consulting$10,902 (45.0%)
Other$8,000 (33.0%)
Research$2,244 (9.3%)
Travel$1,635 (6.7%)
Food & Beverage$1,137 (4.7%)
Education$326.99 (1.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $10,902 | 8 | 45.0% |
| Honoraria | $8,000 | 3 | 33.0% |
| Unspecified | $2,244 | 8 | 9.3% |
| Travel and Lodging | $1,635 | 6 | 6.7% |
| Food and Beverage | $1,137 | 14 | 4.7% |
| Education | $326.99 | 4 | 1.3% |
Payments by Type
General
$22,002
35 transactions
Research
$2,244
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| MAYNE PHARMA INC. | $8,489 | 10 | $0 (2022) |
| Octapharma USA, Inc. | $4,486 | 8 | $0 (2019) |
| Astellas Pharma US Inc | $3,204 | 7 | $0 (2023) |
| Melinta Therapeutics, LLC | $3,122 | 4 | $0 (2024) |
| GlaxoSmithKline, LLC. | $2,600 | 2 | $0 (2023) |
| Astellas Pharma Global Development | $2,244 | 8 | $0 (2022) |
| Partner Therapeutics, Inc. | $48.28 | 1 | $0 (2023) |
| AbbVie Inc. | $21.10 | 1 | $0 (2021) |
| Insmed, Inc. | $17.27 | 1 | $0 (2022) |
| Allergan Inc. | $13.60 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,760 | 1 | Melinta Therapeutics, LLC ($2,760) |
| 2023 | $3,833 | 7 | GlaxoSmithKline, LLC. ($2,600) |
| 2022 | $316.67 | 3 | Astellas Pharma Global Development ($175.38) |
| 2021 | $449.72 | 4 | Astellas Pharma Global Development ($428.62) |
| 2020 | $3,825 | 5 | MAYNE PHARMA INC. ($2,665) |
| 2019 | $8,206 | 16 | Octapharma USA, Inc. ($4,486) |
| 2018 | $3,490 | 6 | Mayne Pharma Inc. ($2,757) |
| 2017 | $1,365 | 1 | Astellas Pharma US Inc ($1,365) |
All Payment Transactions
43 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/26/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug) | Consulting Fee | Cash or cash equivalent | $2,760.00 | General |
| Category: ANTIFUNGALS | ||||||
| 11/28/2023 | Partner Therapeutics, Inc. | LEUKINE (Drug) | Food and Beverage | In-kind items and services | $48.28 | General |
| Category: Hematology/Oncology | ||||||
| 11/22/2023 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $1,300.00 | General |
| 10/11/2023 | Melinta Therapeutics, LLC | Rezzayo (Drug) | Food and Beverage | In-kind items and services | $82.47 | General |
| Category: ANTIFUNGALS | ||||||
| 05/17/2023 | Melinta Therapeutics, LLC | Rezzayo (Drug) | Food and Beverage | In-kind items and services | $114.53 | General |
| Category: ANTIFUNGALS | ||||||
| 03/28/2023 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $1,300.00 | General |
| 02/06/2023 | Melinta Therapeutics, LLC | Rezzayo (Drug) | Food and Beverage | In-kind items and services | $165.37 | General |
| Category: ANTIFUNGALS | ||||||
| 01/19/2023 | Astellas Pharma US Inc | Cresemba (Drug) | Consulting Fee | Cash or cash equivalent | $822.00 | General |
| Category: Infectious Diseases | ||||||
| 08/16/2022 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $17.27 | General |
| Category: Respiratory | ||||||
| 07/15/2022 | MAYNE PHARMA INC. | — | Food and Beverage | In-kind items and services | $124.02 | General |
| 01/19/2022 | Astellas Pharma Global Development | Cresemba (Drug) | — | In-kind items and services | $175.38 | Research |
| Study: A Non-Interventional Registry Study of Systemic Antifungal Therapy in Adult Subjects with Invasive Mucormycosis or Invasive Aspergillosis Caused by a Non-fumigatus Species • Category: Infectious Diseases | ||||||
| 08/24/2021 | AbbVie Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $21.10 | General |
| Category: ANTI-INFECTIVE | ||||||
| 08/17/2021 | Astellas Pharma Global Development | CRESEMBA (Drug) | — | In-kind items and services | $175.38 | Research |
| Study: A Non-Interventional Registry Study of Systemic Antifungal Therapy in Adult Subjects with Invasive Mucormycosis or Invasive Aspergillosis Caused by a Non-fumigatus Species • Category: HOSPITAL AND TRANSPLANT | ||||||
| 07/22/2021 | Astellas Pharma Global Development | CRESEMBA (Drug) | — | In-kind items and services | $126.62 | Research |
| Study: A Non-Interventional Registry Study of Systemic Antifungal Therapy in Adult Subjects with Invasive Mucormycosis or Invasive Aspergillosis Caused by a Non-fumigatus Species • Category: HOSPITAL AND TRANSPLANT | ||||||
| 06/23/2021 | Astellas Pharma Global Development | CRESEMBA (Drug) | — | In-kind items and services | $126.62 | Research |
| Study: A Non-Interventional Registry Study of Systemic Antifungal Therapy in Adult Subjects with Invasive Mucormycosis or Invasive Aspergillosis Caused by a Non-fumigatus Species • Category: HOSPITAL AND TRANSPLANT | ||||||
| 12/10/2020 | Astellas Pharma Global Development | CRESEMBA (Drug) | — | In-kind items and services | $166.44 | Research |
| Study: A NON-INTERVENTIONAL REGISTRY STUDY OF SYSTEMIC ANTIFUNGAL THERAPY IN ADULT SUBJECTS WITH INVASIVE MUCORMYCOSIS OR INVASIVE ASPERGILLOSIS CAUSED BY A NON-FUMIGATUS SPECIES PROTOCOL FOR PHASE 4 STUDY OF ASP9766 • Category: HOSPITAL AND TRANSPLANT | ||||||
| 07/02/2020 | MAYNE PHARMA INC. | TOLSURA (Drug) | Consulting Fee | Cash or cash equivalent | $615.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 06/12/2020 | MAYNE PHARMA INC. | TOLSURA (Drug) | Consulting Fee | Cash or cash equivalent | $2,050.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/30/2020 | Astellas Pharma Global Development | CRESEMBA (Drug) | — | In-kind items and services | $675.00 | Research |
| Study: A NON-INTERVENTIONAL REGISTRY STUDY OF SYSTEMIC ANTIFUNGAL THERAPY IN ADULT SUBJECTS WITH INVASIVE MUCORMYCOSIS OR INVASIVE ASPERGILLOSIS CAUSED BY A NON-FUMIGATUS SPECIES PROTOCOL FOR PHASE 4 STUDY OF ASP9766 • Category: HOSPITAL AND TRANSPLANT | ||||||
| 04/18/2020 | Astellas Pharma Global Development | CRESEMBA (Drug) | — | In-kind items and services | $319.00 | Research |
| Study: A NON-INTERVENTIONAL REGISTRY STUDY OF SYSTEMIC ANTIFUNGAL THERAPY IN ADULT SUBJECTS WITH INVASIVE MUCORMYCOSIS OR INVASIVE ASPERGILLOSIS CAUSED BY A NON-FUMIGATUS SPECIES PROTOCOL FOR PHASE 4 STUDY OF ASP9766 • Category: HOSPITAL AND TRANSPLANT | ||||||
| 11/26/2019 | Astellas Pharma Global Development | CRESEMBA (Drug) | — | In-kind items and services | $480.00 | Research |
| Study: A Non-Interventional Registry Study of Systemic Antifungal Therapy in Adult Subjects with Invasive Mucormycosis or Invasive Aspergillosis Caused by a Non-fumigatus Species Protocol for Phase 4 Study of ASP9766 • Category: INFECTIOUS DISEASES | ||||||
| 10/04/2019 | Mayne Pharma Inc. | DORYX (Drug) | Food and Beverage | In-kind items and services | $181.82 | General |
| Category: DERMATOLOGY | ||||||
| 07/26/2019 | Mayne Pharma Inc. | TOLSURA (Drug) | Honoraria | Cash or cash equivalent | $2,000.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 07/26/2019 | Mayne Pharma Inc. | TOLSURA (Drug) | Travel and Lodging | Cash or cash equivalent | $677.62 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 06/28/2019 | Mayne Pharma Inc. | DORYX (Drug) | Food and Beverage | In-kind items and services | $83.83 | General |
| Category: DERMATOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A NON-INTERVENTIONAL REGISTRY STUDY OF SYSTEMIC ANTIFUNGAL THERAPY IN ADULT SUBJECTS WITH INVASIVE MUCORMYCOSIS OR INVASIVE ASPERGILLOSIS CAUSED BY A NON-FUMIGATUS SPECIES PROTOCOL FOR PHASE 4 STUDY OF ASP9766 | Astellas Pharma Global Development | $1,160 | 3 |
| A Non-Interventional Registry Study of Systemic Antifungal Therapy in Adult Subjects with Invasive Mucormycosis or Invasive Aspergillosis Caused by a Non-fumigatus Species | Astellas Pharma Global Development | $604.00 | 4 |
| A Non-Interventional Registry Study of Systemic Antifungal Therapy in Adult Subjects with Invasive Mucormycosis or Invasive Aspergillosis Caused by a Non-fumigatus Species Protocol for Phase 4 Study of ASP9766 | Astellas Pharma Global Development | $480.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 126 | 147 | $56,128 | $14,321 |
| 2022 | 7 | 134 | 156 | $53,498 | $15,035 |
| 2021 | 8 | 191 | 258 | $73,933 | $22,358 |
| 2020 | 7 | 128 | 163 | $48,281 | $13,573 |
Total Patients
579
Total Services
724
Medicare Billing
$65,287
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 35 | 36 | $19,668 | $3,685 | 18.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 26 | 31 | $7,316 | $3,047 | 41.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 15 | 17 | $5,916 | $2,409 | 40.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 17 | 17 | $12,957 | $2,340 | 18.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 22 | 35 | $8,610 | $2,197 | 25.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 11 | 11 | $1,661 | $642.69 | 38.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 28 | 32 | $11,136 | $4,506 | 40.5% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 33 | 33 | $18,327 | $3,566 | 19.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 14 | 14 | $8,638 | $2,203 | 25.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 15 | 17 | $4,012 | $1,741 | 43.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 15 | 25 | $5,670 | $1,415 | 25.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 12 | 13 | $1,963 | $923.64 | 47.1% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 17 | 22 | $3,752 | $680.47 | 18.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 27 | 70 | $13,860 | $4,032 | 29.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 24 | 24 | $14,316 | $3,538 | 24.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 21 | 26 | $9,294 | $3,318 | 35.7% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 30 | 30 | $13,317 | $3,200 | 24.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 22 | 28 | $6,568 | $2,919 | 44.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 26 | 34 | $5,086 | $2,429 | 47.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 11 | 11 | $7,012 | $1,868 | 26.6% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 30 | 35 | $4,480 | $1,054 | 23.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 29 | 36 | $8,502 | $3,105 | 36.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 19 | 26 | $8,736 | $3,041 | 34.8% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 16 | 16 | $10,622 | $2,375 | 22.4% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 17 | 17 | $8,493 | $1,914 | 22.5% |
About Dr. Andrej Spec, MD
Dr. Andrej Spec, MD is a Infectious Disease healthcare provider based in Saint Louis, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/12/2010. The National Provider Identifier (NPI) number assigned to this provider is 1922326297.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Andrej Spec, MD has received a total of $24,246 in payments from pharmaceutical and medical device companies, with $2,760 received in 2024. These payments were reported across 43 transactions from 10 companies. The most common payment nature is "Consulting Fee" ($10,902).
As a Medicare-enrolled provider, Spec has provided services to 579 Medicare beneficiaries, totaling 724 services with total Medicare billing of $65,287. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Saint Louis, MO
- Active Since 05/12/2010
- Last Updated 04/17/2025
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1922326297
Products in Payments
- TOLSURA (Drug) $5,343
- OCTAGAM IMMUNE GLOBULIN (HUMAN) (Biological) $4,486
- Rezzayo (Drug) $3,122
- CRESEMBA (Drug) $2,759
- TOLSURA - 60 CAPSULE (Drug) $2,500
- Cresemba (Drug) $997.38
- DORYX (Drug) $522.21
- LEUKINE (Drug) $48.28
- DALVANCE (Drug) $21.10
- Arikayce (Drug) $17.27
- TEFLARO (Drug) $13.60
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Saint Louis
Robert Belshe, Md, MD
Infectious Disease — Payments: $421,832
Infectious Disease $421,832
Dr. Erik Dubberke, Md, MD
Infectious Disease — Payments: $161,161
Infectious Disease $161,161
William Summers, Md, MD
Infectious Disease — Payments: $128,640
Infectious Disease $128,640
Dr. Rupa Patel, Md, MD
Infectious Disease — Payments: $116,585
Infectious Disease $116,585
Dr. William Powderly, Md, MD
Infectious Disease — Payments: $52,771
Infectious Disease $52,771
Dr. Michael Diamond, Md, MD
Infectious Disease — Payments: $44,261
Infectious Disease $44,261